FR2347382B1 - - Google Patents
Info
- Publication number
- FR2347382B1 FR2347382B1 FR7710271A FR7710271A FR2347382B1 FR 2347382 B1 FR2347382 B1 FR 2347382B1 FR 7710271 A FR7710271 A FR 7710271A FR 7710271 A FR7710271 A FR 7710271A FR 2347382 B1 FR2347382 B1 FR 2347382B1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0011—Unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB13707/76A GB1581234A (en) | 1976-04-05 | 1976-04-05 | 11a - amino - 3a - hydroxysteroids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2347382A1 FR2347382A1 (en) | 1977-11-04 |
| FR2347382B1 true FR2347382B1 (en) | 1982-01-08 |
Family
ID=10027931
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7710271A Granted FR2347382A1 (en) | 1976-04-05 | 1977-04-05 | 11A-AMINO, D4 OR D5 PREGNANES AND ANDROSTANES WITH DISUBSTITUTED AMINO GROUP |
| FR8110329A Withdrawn FR2485020A1 (en) | 1976-04-05 | 1981-05-25 | 11A-AMINO, 4 OR 5 PREGNANES AND ANDROSTANES |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8110329A Withdrawn FR2485020A1 (en) | 1976-04-05 | 1981-05-25 | 11A-AMINO, 4 OR 5 PREGNANES AND ANDROSTANES |
Country Status (19)
| Country | Link |
|---|---|
| JP (1) | JPS52142056A (en) |
| AU (1) | AU517206B2 (en) |
| BE (1) | BE853227A (en) |
| DE (1) | DE2715078A1 (en) |
| DK (1) | DK148677A (en) |
| ES (1) | ES457507A1 (en) |
| FI (1) | FI771046A (en) |
| FR (2) | FR2347382A1 (en) |
| GB (1) | GB1581234A (en) |
| IE (1) | IE45276B1 (en) |
| IL (1) | IL51816A (en) |
| IT (1) | IT1073232B (en) |
| LU (1) | LU77064A1 (en) |
| NL (1) | NL7703667A (en) |
| NO (1) | NO771197L (en) |
| NZ (1) | NZ183775A (en) |
| PL (1) | PL197186A1 (en) |
| SE (1) | SE7703929L (en) |
| ZA (1) | ZA772029B (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7288081A (en) * | 1980-07-16 | 1982-01-21 | Glaxo Group Limited | 11alpha-amino-androstanes |
| SE8104393L (en) * | 1980-07-16 | 1982-01-17 | Glaxo Group Ltd | LLALFA-AMINO androstanes |
| JPS57158800A (en) * | 1981-03-02 | 1982-09-30 | Glaxo Group Ltd | 11 alpha-amino-3 beta-hydroxyandrostane compound |
| JPS57203099A (en) * | 1981-05-29 | 1982-12-13 | Glaxo Group Ltd | 11 alpha-amino-androstane compound |
| AU8428782A (en) * | 1981-05-29 | 1982-12-02 | Glaxo Group Limited | 11-alpha-amino-androstane |
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| CZ300694A3 (en) * | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
| FR2910002B1 (en) * | 2006-12-13 | 2009-01-30 | Sanofi Aventis Sa | NOVEL METHOD FOR THE DIASTEREOSELECTIVE OBTAINING OF A PRIMARY CHIRAL AMINE ON A STEROID |
| JP2010037243A (en) * | 2008-08-04 | 2010-02-18 | Mitsubishi Rayon Co Ltd | Method for producing norbornene lactone monomer |
| ES2738526T3 (en) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compounds 19-norpregnano 3,3-disubstituted, compositions and uses thereof |
| PL2806877T3 (en) | 2012-01-23 | 2020-06-01 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| SG11201508550XA (en) | 2013-04-17 | 2015-11-27 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| CA2909546C (en) | 2013-04-17 | 2019-01-22 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| SI3021852T1 (en) * | 2013-07-19 | 2021-07-30 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3035940B1 (en) | 2013-08-23 | 2018-10-17 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| PL3206493T3 (en) | 2014-10-16 | 2021-01-25 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| SG10202009861SA (en) | 2014-10-16 | 2020-11-27 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| LT3224269T (en) * | 2014-11-27 | 2020-07-10 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| PL3250210T3 (en) | 2015-01-26 | 2021-07-26 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| DK3258939T3 (en) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF |
| MA43815A (en) | 2016-03-08 | 2021-04-07 | Sage Therapeutics Inc | NEUROACTIVE STEROIDS, COMPOSITIONS, AND THEIR USES |
| CN116162121A (en) | 2016-07-11 | 2023-05-26 | 萨奇治疗股份有限公司 | C17, C20 and C21 substituted neuroactive steroids and methods of use thereof |
| US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| CA3086189A1 (en) * | 2017-12-22 | 2019-06-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA54594A (en) | 2018-12-05 | 2022-04-06 | Sage Therapeutics Inc | NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF |
| MX2021014515A (en) | 2019-05-31 | 2022-03-22 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof. |
| TW202114696A (en) * | 2019-06-27 | 2021-04-16 | 美商賽吉醫療公司 | Compositions and methods for treating cns disorders |
| EP3990468A1 (en) * | 2019-06-27 | 2022-05-04 | Sage Therapeutics, Inc. | Compounds for treating cns disorders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2982775A (en) * | 1957-05-06 | 1961-05-02 | Schering Corp | 11-oximino-, amino- and acylaminosteroids |
-
1976
- 1976-04-05 GB GB13707/76A patent/GB1581234A/en not_active Expired
-
1977
- 1977-04-04 DK DK148677A patent/DK148677A/en not_active IP Right Cessation
- 1977-04-04 NL NL7703667A patent/NL7703667A/en not_active Application Discontinuation
- 1977-04-04 NO NO771197A patent/NO771197L/en unknown
- 1977-04-04 IT IT48805/77A patent/IT1073232B/en active
- 1977-04-04 IE IE712/77A patent/IE45276B1/en unknown
- 1977-04-04 BE BE176410A patent/BE853227A/en not_active IP Right Cessation
- 1977-04-04 AU AU23942/77A patent/AU517206B2/en not_active Expired
- 1977-04-04 FI FI771046A patent/FI771046A/fi not_active Application Discontinuation
- 1977-04-04 NZ NZ183775A patent/NZ183775A/en unknown
- 1977-04-04 PL PL19718677A patent/PL197186A1/en unknown
- 1977-04-04 IL IL51816A patent/IL51816A/en unknown
- 1977-04-04 JP JP3768077A patent/JPS52142056A/en active Pending
- 1977-04-04 LU LU77064A patent/LU77064A1/xx unknown
- 1977-04-04 ZA ZA00772029A patent/ZA772029B/en unknown
- 1977-04-04 DE DE19772715078 patent/DE2715078A1/en not_active Withdrawn
- 1977-04-04 SE SE7703929A patent/SE7703929L/en unknown
- 1977-04-04 ES ES457507A patent/ES457507A1/en not_active Expired
- 1977-04-05 FR FR7710271A patent/FR2347382A1/en active Granted
-
1981
- 1981-05-25 FR FR8110329A patent/FR2485020A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| SE7703929L (en) | 1978-10-27 |
| AU517206B2 (en) | 1981-07-16 |
| BE853227A (en) | 1977-10-04 |
| IL51816A0 (en) | 1977-06-30 |
| DE2715078A1 (en) | 1977-10-13 |
| IE45276B1 (en) | 1982-07-28 |
| NL7703667A (en) | 1977-10-07 |
| AU2394277A (en) | 1978-10-12 |
| GB1581234A (en) | 1980-12-10 |
| IE45276L (en) | 1977-10-05 |
| DK148677A (en) | 1977-10-06 |
| FR2347382A1 (en) | 1977-11-04 |
| NO771197L (en) | 1977-10-06 |
| IT1073232B (en) | 1985-04-13 |
| PL197186A1 (en) | 1979-06-18 |
| NZ183775A (en) | 1979-12-11 |
| JPS52142056A (en) | 1977-11-26 |
| ZA772029B (en) | 1978-11-29 |
| FI771046A (en) | 1977-10-06 |
| FR2485020A1 (en) | 1981-12-24 |
| ES457507A1 (en) | 1978-03-16 |
| LU77064A1 (en) | 1979-01-18 |
| IL51816A (en) | 1981-09-13 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CD | Change of name or company name | ||
| ST | Notification of lapse |